Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale
And the reason is because, as we age, pretty much from the late 20s to early 30s we start losing the ability to produce growth hormone which is pretty much the end hormone in relative regulation and manipulation, I think most importantly, of the mitochondria and then also of the immune system and of immune-regulating cells
Its development program was halted after Phase 2b trials, and it never reached approval as an obesity medication
They work on the growth hormone and IGF-1 axis
For reconstitution protocol, see How to Reconstitute Peptides
BPC-157 is also named on WADA's Prohibited List under section S0 (Non-Approved Substances), the first time WADA named a specific substance by name as an example within that category (added for the 2022 List)